Series B Biotech companies in New York

Companies applying biology, chemistry, and computation to therapeutics and tooling. Filtered to Series B-stage companies headquartered in New York.

Edit the query above, or pick a refinement. 500 free credits on sign-up, no card needed.

Built from a search like: “Top Series B Biotech companies in New York”

Ranked by current headcount across Series B Biotech companies in New York. Refreshed daily.

1
Immunai· New York, New York, United States
Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
- Series B
- 176 employees
- Founded 2019
2
Lifebit· New York, New York, United States
Lifebit powers the federated infrastructure behind national-scale biomedical research. Our platform enables pharma, biobanks, and governments to analyze the world's most sensitive health data — without the data ever leaving its source.Genomics England runs on Lifebit. So do ten of the world's largest biobanks, and research programs spanning the UK, US, and Asia.We built the federated Trusted Research Environment (TRE) from first principles around the ONS Five Safes framework: data stays at source, sovereignty stays with the data controller, and every output passes through an airlock. It's what makes population-scale genomics, federated multi-omic analysis, and cross-border biomedical AI possible without compromising patient trust.For the pharma companies accelerating discovery. For the biobanks safeguarding a generation of consented data. For the governments treating health data as sovereign infrastructure — Lifebit is the operating layer.
- Series B
- 67 employees
- Founded 2017
3
Helaina· New York, New York, United States
Helaina is a biotech company pushing the boundaries of what food can do for health.
- Series B
- 51 employees
- Founded 2019
Live search
This list is a starting point
I can run a natural-language search across LinkedIn, GitHub, and the open web. Fire one of these, or edit the box up top to match exactly who you're after.
- Engineers at top Series B Biotech companies in New YorkRun
- Founders of Series B Biotech companies in New YorkRun
500 free credits on sign-up, no card needed.
4
Envisagenics· New York, New York, United States
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
- Series B
- 37 employees
- Founded 2014
5
HiberCell· New York, New York, United States
HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.
- Series B
- 26 employees
- Founded 2019

6
Prevail Therapeutics· New York, New York, United States
At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
- Series B
- 17 employees
- Founded 2017
7
AnHeart Therapeutics· New York, New York, United States
AnHeart is now a Nuvation Bio company. For the latest news and updates please visit www.linkedin.com/company/nuvationbio/
- Series B
- 17 employees
- Founded 2018
8
Intrommune Therapeutics· New York, New York, United States
Intrommune Therapeutics, Inc. is a biotechnology company located in New York, NY. Intrommune is developing food allergy immunotherapies that are delivered while you brush your teeth, a lifelong habit that is ingrained in most people and ensures daily use of our product. Intrommune's elegant new treatment platform for food allergies is expected to be safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer from peanut allergy.Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 32 million people in the U.S., who suffer from this life-altering condition.
- Series B
- 14 employees
- Founded 2015
9
Treadwell Therapeutics, Inc.· New York, New Mexico, United States
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/
- Series B
- 12 employees
- Founded 2019
10
Alpha Fusion Inc.· New York, New York, United States
Alpha Fusion Inc. is a company based in Tokyo.
- Series B
- 8 employees
- Founded 2021

Reveal 8 more·500 free credits, no card

Find engineers at Series B Biotech companies in New York

Searching for “engineers at top Series B Biotech companies in New York” surfaces this slice of the market. The list above ranks Biotech companies headquartered in New York whose latest disclosed round is Series B, by current headcount, drawn from public LinkedIn and Crunchbase records. With 13 matching companies in Refolk’s index, this is a tight read on where the Biotech talent in New York is heating up.

Three filters at once narrows the field hard. The companies that survive all three - Series B, Biotech, in New York - are usually the most targeted recruiting pool a hiring manager can ask for. Senior engineers, founding designers, and product leads here are about to become Biotech’s next operators and angel investors.

Refolk converts this list into a live search. Ask for “senior engineers at Series B Biotech companies in New York hiring” or “founders of Series B Biotech companies in New York who left in the last year” and Refolk returns a ranked shortlist with the evidence behind each match.

How this list is built

Refolk pulled Biotech companies headquartered in New York whose latest disclosed funding round is Series B from public LinkedIn and Crunchbase records, ranked them by current employee count, and kept those with at least 3 employees. The list refreshes once a day.

Last refreshed: Wed, 05 Aug 2026 16:58:14 GMT

Search this list

Need an even more specific search?

Refolk runs natural-language searches across LinkedIn, GitHub, and the open web. Try one of these:

500 free credits on sign-up, no card needed.

Related lists

See all company lists.

Slice this list a different way

Common questions

How is this ranking built?

The list draws on the public company graph - headcount and growth signals, funding history, and recency. The criteria chips at the top show exactly which filters produced it, and the methodology section explains the ranking.

How fresh is the data?

The underlying index updates continuously and this page re-renders at least daily. Last refreshed: Wed, 05 Aug 2026 16:58:14 GMT.

Can I find the people inside these companies?

Yes. Ask in plain English - for example "engineering leaders at these companies who joined in the last year" - and I return the specific people, with context on each.

Try it on your own search

Stop building boolean strings. Just describe the person.

Type one sentence and I plan the search, read GitHub, public LinkedIn and Crunchbase records, and the open web live, then hand back a ranked shortlist with the reasoning behind every name. No filters to learn, no export to clean up, no sales call to sit through.

One sentence in, a ranked shortlist out. No boolean, no filters, no seat to buy.
Read live at search time, not from a database that went stale last quarter.
Watch every step as it runs, and see why each name made the list.

500 free credits on sign-up. No card, no demo call. See real searches.

This list is a starting point